PLACENTEX ® Polydeoxyribonucleotide ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
51	全身性強皮症	2

51. 全身性強皮症

---

臨床試験数 : 525 /  薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03388255 (ClinicalTrials.gov)	November 8, 2016	21/12/2017	Efficacy and Safety of PLACENTEX ® i.m. in Patients With Scleroderma Diseases	A Phase IV, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of PLACENTEX ® Polydeoxyribonucleotide i.m. in Patients With Fibrotic and Atrophic Cutaneous Lesions in Scleroderma Diseases	Scleroderma Disease	Drug: Polydeoxyribonucleotides	Mastelli S.r.l	Sintesi Research Srl	Terminated	18 Years	N/A	All	25	Phase 4	Italy
2	EUCTR2015-005100-28-IT (EUCTR)	18/07/2016	17/01/2022	A clinical trial to evaluate the efficacy and safety of PLACENTEX ¿ administered intra-muscular in patients with cutaneous lesions in scleroderma diseases.	A phase IV, single-arm, open-label clinical trial to evaluate the efficacy and safety of PLACENTEX ¿ Polydeoxyribonucleotide i.m. in patients with fibrotic and atrophic cutaneous lesions in scleroderma diseases. - A clinical trial to evaluate the efficacy and safety of PLACENTEX ¿ administered intra-muscular in p	Fibrotic and atrophic cutaneous lesions in localized scleroderma diseases. MedDRA version: 20.0;Level: HLT;Classification code 10039711;Term: Scleroderma and associated disorders;System Organ Class: 100000004870;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]	Trade Name: PLACENTEX ¿5.625 mg/3 ml soluzione iniettabile¿ Product Name: PLACENTEX ¿ Polydeoxyribonucleotide 5.625 mg/3 ml INN or Proposed INN: POLYDEOXYRIBONUCLEOTIDES Other descriptive name: PLACENTEX ® Polydeoxyribonucleotide	MASTELLI SRL	NULL	Not Recruiting			Female: yes Male: yes	45	Phase 4	Italy